Display options
Cite
Igarashi K, Kawaguchi K, Kiyuna T, et al. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2017;8(44):75874-75880doi: 10.18632/oncotarget.16548.
Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S. D., Dry, S. M., Li, Y., Singh, A. S., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F. C., & Hoffman, R. M. (2017). Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget, 8(44), 75874-75880. https://doi.org/10.18632/oncotarget.16548
Igarashi, Kentaro, et al. "Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model." Oncotarget vol. 8,44 (2017): 75874-75880. doi: https://doi.org/10.18632/oncotarget.16548
Igarashi K, Kawaguchi K, Kiyuna T, Murakami T, Miwa S, Nelson SD, Dry SM, Li Y, Singh AS, Kimura H, Hayashi K, Yamamoto N, Tsuchiya H, Eilber FC, Hoffman RM. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2017 Mar 24;8(44):75874-75880. doi: 10.18632/oncotarget.16548. eCollection 2017 Sep 29. PMID: 29100276; PMCID: PMC5652670.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Mar 24;8(44):75874-75880. doi: 10.18632/oncotarget.16548. eCollection 2017 Sep 29.

Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.

Oncotarget

Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, Takashi Murakami, Shinji Miwa, Scott D Nelson, Sarah M Dry, Yunfeng Li, Arun S Singh, Hiroaki Kimura, Katsuhiro Hayashi, Norio Yamamoto, Hiroyuki Tsuchiya, Fritz C Eilber, Robert M Hoffman

Affiliations

  1. AntiCancer, Inc., San Diego, CA, USA.
  2. Department of Surgery, University of California, San Diego, CA, USA.
  3. Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan.
  4. Department of Pathology, University of California, Los Angeles, CA, USA.
  5. Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.
  6. Division of Surgical Oncology, University of California, Los Angeles, CA, USA.

PMID: 29100276 PMCID: PMC5652670 DOI: 10.18632/oncotarget.16548

Abstract

Adult pleomorphic rhabdomyosarcoma (RMS) is a rare and recalcitrant, highly-malignant mesenchymal tumor in need of improved therapeutic strategies. Our laboratory pioneered the patient-derived orthotopic xenograft (PDOX) nude mouse model with the technique of surgical orthotopic implantation (SOI). We previously described the development of a PDOX model of adult pleomorphic RMS where the tumor behaved similar to the patient donor. A high-grade pleomorphic rhabdomyosarcoma from a striated muscle was previously grown orthotopically in the right biceps-femoris muscle of nude mice to establish the PDOX model. In the present study, the PDOX models were randomized into the following treatment groups when tumor volume reached 100 mm

Keywords: combination; irinotecan; nude mice; patient-derived orthotopic xenograft (PDOX); rhabdomosarcoma; temozolomide

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Oncotarget. 2016 Jul 26;7(30):47556-47564 - PubMed
  2. Anticancer Res. 1993 Mar-Apr;13(2):283-6 - PubMed
  3. Drug Discov Today. 2003 Dec 15;8(24):1104-7 - PubMed
  4. Cancer. 1993 Mar 1;71(5):1904-22 - PubMed
  5. J Pediatr Surg. 1989 Jan;24(1):5-10 - PubMed
  6. Oncotarget. 2016 Nov 1;7(44):71737-71743 - PubMed
  7. PLoS One. 2014 Dec 02;9(12):e114310 - PubMed
  8. Nat Rev Cancer. 2017 Apr;17 (4):254-268 - PubMed
  9. PLoS One. 2015 Feb 17;10(2):e0117417 - PubMed
  10. Int J Cancer. 1992 Jul 30;51(6):992-5 - PubMed
  11. Cancer. 1995 Sep 15;76(6):1073-85 - PubMed
  12. Pediatr Blood Cancer. 2010 Jul 1;54(7):909-15 - PubMed
  13. Int J Cancer. 1993 Feb 20;53(4):608-12 - PubMed
  14. Cell Cycle. 2005 Nov;4(11):1518-21 - PubMed
  15. Cancer. 1988 Jan 15;61(2):209-20 - PubMed
  16. Pediatr Blood Cancer. 2009 Dec;53(6):1029-34 - PubMed
  17. J Surg Oncol. 2015 Mar;111(3):311-5 - PubMed
  18. Br J Cancer. 2003 Oct 6;89(7):1147-51 - PubMed
  19. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5645-9 - PubMed
  20. N Engl J Med. 1999 Jul 29;341(5):342-52 - PubMed
  21. PLoS One. 2015 Aug 03;10(8):e0134324 - PubMed
  22. PLoS One. 2016 Aug 08;11(8):e0160882 - PubMed
  23. Cancer. 1988 Oct 1;62(7):1257-66 - PubMed
  24. J Clin Oncol. 2006 Aug 20;24(24):3844-51 - PubMed
  25. Oncotarget. 2016 Dec 27;7(52):85929-85936 - PubMed
  26. Anticancer Res. 2015 Feb;35(2):697-701 - PubMed
  27. Oncotarget. 2016 May 31;7(22):33046-54 - PubMed
  28. J Laparoendosc Adv Surg Tech A. 2014 Apr;24(4):241-7 - PubMed
  29. Oncotarget. 2011 Mar;2(3):222-33 - PubMed
  30. Leukemia. 2006 Mar;20(3):385-91 - PubMed
  31. J Surg Oncol. 2014 Apr;109(5):451-8 - PubMed
  32. Oncotarget. 2016 Mar 15;7(11):12783-90 - PubMed
  33. Anticancer Res. 1993 Jul-Aug;13(4):901-4 - PubMed
  34. Clin Cancer Res. 2004 Feb 1;10 (3):840-8 - PubMed
  35. Oncotarget. 2014 Dec 15;5(23):12346-57 - PubMed
  36. Leukemia. 2001 Jun;15(6):936-41 - PubMed
  37. Pediatr Dev Pathol. 1998 Nov-Dec;1(6):550-61 - PubMed
  38. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9345-9 - PubMed
  39. Tumori. 2016 Nov 11;102(Suppl. 2): - PubMed
  40. Cell Cycle. 2017 Jan 2;16(1):91-94 - PubMed

Publication Types